Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCCam in relapsed chronic lymphocytic leukemia
NCT00147901Phase 2Completed
- Sponsor
- German CLL Study Group
- Start
- Jan 2005
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by German CLL Study Group. Started Jan 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00147901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00147901.